<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS200057</article-id><article-id pub-id-type="doi">10.1101/2024.11.09.622781</article-id><article-id pub-id-type="archive">PPR938240</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Sex-dependent additive effects of dorzagliatin and incretin on insulin secretion in a novel mouse model of <italic>GCK</italic>-MODY</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Salazar</surname><given-names>Shadai</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Delgadillo-Silva</surname><given-names>Luis Fernando</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Carapeto</surname><given-names>Priscila</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dakessian</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Melhem</surname><given-names>Rana</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Provencher-Girard</surname><given-names>Audrey</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ostinelli</surname><given-names>Giada</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Turgeon</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kaci</surname><given-names>Imane</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Migneault</surname><given-names>Francis</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huising</surname><given-names>Mark O.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hébert</surname><given-names>Marie-Josée</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rutter</surname><given-names>Guy A.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="aff" rid="A8">8</xref></contrib></contrib-group><aff id="A1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0161xgx34</institution-id><institution>CR-CHUM and University of Montreal</institution></institution-wrap>, <state>QC</state>, <country country="CA">Canada</country></aff><aff id="A3"><label>3</label>Department of Physiology and Membrane Biology, School of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California</institution></institution-wrap>, <city>Davis</city>, <state>Davis</state>, <country country="CA">CA</country></aff><aff id="A2"><label>2</label>Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05rrcem69</institution-id><institution>University of California</institution></institution-wrap>, <city>Davis</city>, <state>Davis</state>, <country country="CA">CA</country></aff><aff id="A4"><label>4</label>Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0161xgx34</institution-id><institution>Université de Montréal</institution></institution-wrap>, <city>Montréal</city>, <state>QC</state>, <country country="CA">Canada</country></aff><aff id="A5"><label>5</label>Département de Médecine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0161xgx34</institution-id><institution>Université de Montréal</institution></institution-wrap>, <city>Montréal</city>, <state>QC</state>, <country country="CA">Canada</country></aff><aff id="A6"><label>6</label>Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Faculty of Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <addr-line>Hammersmith Hospital</addr-line>, <postal-code>W12 ONN</postal-code><city>London</city><country country="GB">U.K</country></aff><aff id="A7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>Research Institute of the McGill University Health Centre</institution></institution-wrap>, <city>Montreal</city>, <state>QC</state>, <country country="CA">Canada</country></aff><aff id="A8"><label>8</label>Lee Kong Chian School of Medicine, Nanyang Technological College, Singapore</aff><author-notes><corresp id="CR1">Correspondence to <email>g.rutter@imperial.ac.uk</email> or <email>guy.rutter@umontreal.ca</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>13</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>11</day><month>11</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">CC BY-NC 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Glucokinase (GK) catalyses the key regulatory step in glucose-stimulated insulin secretion. Correspondingly, hetero- and homozygous mutations in human <italic>GCK</italic> cause maturity-onset diabetes of the young (GCK-MODY) and permanent neonatal diabetes (PNDM), respectively. To explore the possible utility of glucokinase activators (GKA) and of glucagon–like receptor-1 (GLP-1) agonists in these diseases, we have developed a novel hypomorphic <italic>Gck</italic> allele in mice encoding an aberrantly spliced mRNA deleted for exons 2 and 3. In islets from homozygous knock-in (Gck<sup>KI/KI</sup>) mice, GK immunoreactivity was reduced by &gt;85%, and glucose-stimulated insulin secretion eliminated. Homozygous Gck<sup>KI/KI</sup> mice were smaller than wildtype littermates and displayed frank diabetes (fasting blood glucose &gt;18 mmol/L; HbA1c ~12%), ketosis and nephropathy. Heterozygous Gck<sup>KI/+</sup> mice were glucose intolerant (HbA1c ~5.5%). Abnormal glucose- stimulated Ca<sup>2+</sup> dynamics and beta cell-beta cell connectivity in Gck<sup>KI/+</sup> islets were completely reversed by the recently-developed GKA, dorzagliatin, which was largely inactive in homozygous Gck<sup>KI/KI</sup> mouse islets. The GLP-1 receptor agonist exendin-4 improved glucose tolerance in male Gck<sup>KI/+</sup> mice, an action potentiated by dorzagliatin, in male but not female mice. Sex-dependent additive effects of these agents were also observed on insulin secretion <italic>in vitro</italic>. Combined treatment with GKA and incretin may thus be useful in <italic>GCK</italic>-MODY or <italic>GCK</italic>-PNDM.</p></abstract><kwd-group><kwd>Glucokinase</kwd><kwd>GCK-MODY</kwd><kwd>incretin</kwd><kwd>GCK-PNDM</kwd><kwd>insulin secretion</kwd><kwd>islet</kwd><kwd>beta cell</kwd><kwd>mouse model</kwd><kwd>calcium imaging</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Diabetes affects more than 1 in 10 of the global adult population (<xref ref-type="bibr" rid="R1">1</xref>), a figure expected to grow to &gt;750m people by 2045 (<xref ref-type="bibr" rid="R2">2</xref>). Glucokinase (Hexokinase-4, HK-IV, EC 2.7.1.1, GK) catalyses the flux-generating step in glycolysis and has been dubbed the “glucose sensor” of the pancreatic beta cell (<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R7">7</xref>). After phosphorylation by GK, glucose carbons flow through the glycolytic pathway and enter the citrate cycle, stimulating respiratory chain activity to increase cytosolic ATP/ADP ratios. Closure of ATP-sensitive K+ channels leads to depolarisation of the plasma membrane, Ca<sup>2+</sup> influx through voltage-gated calcium channels, and insulin release (<xref ref-type="bibr" rid="R8">8</xref>; <xref ref-type="bibr" rid="R9">9</xref>). Roles for other coupling factors (<xref ref-type="bibr" rid="R10">10</xref>; <xref ref-type="bibr" rid="R11">11</xref>), and local ATP/ADP microdomains (<xref ref-type="bibr" rid="R12">12</xref>), are also proposed (<xref ref-type="bibr" rid="R13">13</xref>), though the latter are disputed (<xref ref-type="bibr" rid="R14">14</xref>).</p><p id="P3">Homozygosity for GK (<italic>GCK)</italic> loss-of-function (LoF) alleles results in permanent neonatal diabetes mellitus (PNDM) (<xref ref-type="bibr" rid="R15">15</xref>), often requiring insulin treatment shortly after birth (<xref ref-type="bibr" rid="R16">16</xref>–<xref ref-type="bibr" rid="R18">18</xref>). Heterozygosity for LoF mutations is associated with maturity onset diabetes of the young (MODY) (<xref ref-type="bibr" rid="R19">19</xref>; <xref ref-type="bibr" rid="R20">20</xref>). <italic>GCK</italic>-MODY (formerly MODY2) accounts for 20-30% of all MODY cases. Although chronically hyperglycemic (fasting glucose 6-8 mM) (<xref ref-type="bibr" rid="R21">21</xref>), <italic>GCK</italic>-MODY patients are largely asymptomatic (<xref ref-type="bibr" rid="R21">21</xref>). However, fetal macrosomia is an important complication in pregnancy (<xref ref-type="bibr" rid="R22">22</xref>).</p><p id="P4">Several mouse models have been generated to explore how <italic>Gck</italic> insufficiency impacts whole body metabolism (<xref ref-type="bibr" rid="R23">23</xref>). Animals deleted for exon 2 and incorporating a frameshift mutation (<xref ref-type="bibr" rid="R24">24</xref>), or exon 4 plus parts of exons 3 and 5 (<xref ref-type="bibr" rid="R25">25</xref>), respectively show <italic>in utero</italic> or perinatal mortality as homozygotes, and mild hyperglycemia as heterozygotes. Beta cell-selective <italic>Gck</italic> knock-outs display severe hyperglycemia, and die a few days after birth (<xref ref-type="bibr" rid="R26">26</xref>; <xref ref-type="bibr" rid="R27">27</xref>). Demonstrating the importance of islet dysfunction in the impact of these mutations, rescue of <italic>Gck</italic> expression selectively in the beta cell of <italic>Gck</italic> null mice is sufficient to reverse lethality (<xref ref-type="bibr" rid="R25">25</xref>).</p><p id="P5">Incretin drugs including glucagon-like-1 (GLP-1) receptor agonists are now used widely in the clinic and provide a highly efficient treatment for T2D (<xref ref-type="bibr" rid="R28">28</xref>). Use of these agonists has not, up to now, been explored either in <italic>GCK</italic>-MODY or <italic>GCK</italic>-PNDM. In any case, incretin action on insulin secretion requires glucose metabolism (<xref ref-type="bibr" rid="R28">28</xref>), suggesting that the effects of these agents may be limited in the above diseases.</p><p id="P6">Dorzagliatin (<xref ref-type="bibr" rid="R29">29</xref>) is a latest-generation allosteric glucokinase activator (GKA), that has recently been shown to be therapeutically useful in <italic>GCK</italic>-MODY (<xref ref-type="bibr" rid="R30">30</xref>). The above findings raise the possibility that the combined use of incretins and GKA may provide additional benefits compared to the use of either agent alone.</p><p id="P7">Here, we explore this possibility in wildtype mice and in animals bearing a hypomorphic <italic>Gck</italic> allele that results in aberrant splicing and severe depletion of active GK protein. Residual GK activity is nevertheless sufficient to allow the survival of homozygous mice into adulthood, despite severe diabetes, modelling <italic>GCK</italic>-PNDM. Heterozygous Gck<sup>KI/+</sup> mice provide a convenient model of <italic>GCK</italic>-MODY. We test the potential therapeutic utility of glucokinase activators and incretins in both models.</p></sec><sec id="S2" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S3"><title>Generation of hypomorphic <italic>Gck</italic> (C57BL6/J-Gck<sup>tm1(mCard)/Rutt</sup>, Gck<sup>KI</sup>) alleles</title><p id="P8">The overall strategy, as designed with GenOway (Grenoble, Fr), is illustrated in <xref ref-type="fig" rid="F1">Fig. 1A</xref> and <xref ref-type="supplementary-material" rid="SD1">SFig. 1</xref>. Integration of the mutant allele was confirmed by Sanger sequencing. Assessed after mRNA extraction from isolated islets of homozygous male Gck-mCardinal (<italic>Gck</italic>K<sup>I/KI</sup>) mice, amplification by conventional PCR of the region from exon 1 to exon 9 of mRNA-derived cDNA from (<xref ref-type="supplementary-material" rid="SD1">SFig. 1B</xref>) yielded a barely-detectable band corresponding to the predicted wild-type (WT) product (~1.17kb) alongside a major product of ~850bp (~350bp less than predicted). Sanger sequencing of the latter revealed an aberrant splicing event between exons 1 and 4, eliminating the whole of exons 2 and 3 (<xref ref-type="fig" rid="F1">Fig. 1B</xref>, <xref ref-type="supplementary-material" rid="SD1">SFig. 1C</xref>). <italic>In silico</italic> translation of the aberrantly-spliced isoform suggested the production of a 360 amino acids (AA) protein versus native wild type (466 AA) glucokinase. The mutant form is expected to lack amino acids 16 to 121, including residues in the small lobe encoded by exon 3, and critical for ATP binding and catalysis, e.g. R63 (<xref ref-type="bibr" rid="R6">6</xref>; <xref ref-type="bibr" rid="R31">31</xref>; <xref ref-type="bibr" rid="R32">32</xref>) .</p><p id="P9">cDNAs corresponding to the expected IRES or mCardinal regions were not detected in islets, and mCardinal fluorescence was absent from islet, liver and brain (ventromedial and lateral hypothalamus) (<xref ref-type="bibr" rid="R33">33</xref>) (not shown).</p></sec><sec id="S4"><title>Animal husbandry</title><p id="P10">All experimental manipulations were approved by the local ethical committee (CRCHUM, Montreal CIPA 2022–10,040 CM21022GRs). Colonies of GK<sup>KI</sup> and of GK<sup>KI</sup>:Ins1Cre:GCaMP6<sup>f/f</sup> and GK<sup>KI</sup>:Ins1Cre:GCCaMP6<sup>f/f</sup> mice, in which the Ca<sup>2+</sup> sensor GCaMP6f is expressed selectively in the beta cell (<xref ref-type="bibr" rid="R34">34</xref>), on a C57BL/6J background, were fed a regular chow diet and maintained at controlled temperature (21–23 °C), humidity (45–50 %) and light (12 h day-night cycle).</p></sec><sec id="S5"><title>Structural modelling</title><p id="P11">We compared the Alpha fold-predicted 3D protein structure against the X-ray crystal-resolved human Glucokinase (3VEY, <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/structure/3VEY">www.rcsb.org/structure/3VEY</ext-link>). Additionally, we compared the previously AI-generated model of mouse Glucokinase (<xref ref-type="bibr" rid="R35">35</xref>). The 3D comparison was generated by PDB Mol View (Pairwise Structure Alignment <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/alignment">https://www.rcsb.org/alignment</ext-link>) using the TM-algin method. The TM-align method is based on structure comparison for proteins with similar global topology. ClustalW was employed to quantify amino acid sequence similarity.</p></sec><sec id="S6"><title>Intraperitoneal glucose tolerance tests (IPGTT)</title><p id="P12">Mice were fasted overnight (16h) with free access to water. At 9 am, glucose (2g/kg body weight) was administered <italic>via</italic> intraperitoneal injection. Blood glucose levels were measured from the tail vein 0, 15, 30, 60 and 90min. later with an automatic glucometer (Contour next ONE; Canada) (<xref ref-type="bibr" rid="R36">36</xref>).</p></sec><sec id="S7"><title>Insulin tolerance tests</title><p id="P13">After 6h fasting with free access to water, human insulin (Novolin-ge Toronto, Novo Nordisk) (1U/kg body weight) was administered <italic>via</italic> intraperitoneal injection. Blood glucose was measured as above (<xref ref-type="bibr" rid="R36">36</xref>).</p></sec><sec id="S8"><title>Islet isolation</title><p id="P14">Islets were isolated from mice aged between 8 and 16 weeks, essentially as previously described (<xref ref-type="bibr" rid="R37">37</xref>).</p></sec><sec id="S9"><title>Measurement of insulin secretion <italic>in vitro</italic></title><p id="P15">Initially, insulin secretion was assessed using the following buffer, containing (mmol/L) 137 NaCl, 4.8 KCl, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 1.2 MgSO<sub>4</sub>, 2.5 CaCl<sub>2</sub>·2H2O, 5 NaHCO<sub>3</sub>, and 16 HEPES, adjusted to pH 7.4 and supplemented with 0.1% BSA. Islets were pre-incubated in low glucose (3 mM) for 1 h, the sequentially for 1 h at 3 mmol/L then 17 mmol/L glucose (see <xref ref-type="fig" rid="F3">Fig. 3, H,I</xref>). In experiments involving agonist treatment (<xref ref-type="fig" rid="F6">Fig. 6</xref>), isolated islets were incubated in modified KRBH stock solutions comprising (mmol/L) 10 HEPES, 2 NaHCO<sub>3</sub>, 137 NaCl, 3.6 KCl, 0.5 NaH<sub>2</sub>PO4, 0.5 MgSO4, 1.5 CaCl<sub>2</sub>. Solutions were gassed with 95% O<sub>2</sub> and 5% CO<sub>2</sub> and adjusted to pH 7.4. The buffer was maintained at 37°C and supplemented with 0.1% BSA. Islets were selected based on size, washed, and incubated in KRBH-BSA with 3 mmol/L glucose for 1 h then transferred to 12-well plates and divided into four groups, each in triplicate: (<xref ref-type="bibr" rid="R1">1</xref>) control (<xref ref-type="bibr" rid="R2">2</xref>) plus Dorzagliatin (10 μM), (<xref ref-type="bibr" rid="R3">3</xref>) Exendin-4 (100 nmol/L), (<xref ref-type="bibr" rid="R4">4</xref>) Dorzagliatin and Exendin-4. Islets were incubated for 30 min. in low glucose (3 mmol/L), then at high (17 mmol/L) glucose. All samples were stored at -80°C until measurement using an Insulin Ultrasensitive HTRF Assay Kit (Revvity, 62IN2PEG).</p></sec><sec id="S10"><title>Beta- and alpha-cell mass</title><p id="P16">After transcardiac perfusion, the pancreas was carefully dissected, weighed, and placed in cassettes for fixation in 4%(v/v) paraformaldehyde (PFA) for 2h to facilitate paraffin embedding. Adjacent full footprint sections were then subjected to immunostaining for glucagon (Cell Signaling, 2760) or insulin (Cell Signaling, 4590) using a standard DAB substrate kit (Cell Signaling, 8059). Incubations with primary antibodies were performed overnight at 4°C, at an antibody dilution of 1:100. The mass of β-cells and α-cells was quantified using point counting morphometry (<xref ref-type="bibr" rid="R38">38</xref>).</p></sec><sec id="S11"><title>Renal histology</title><p id="P17">Whole kidney was dissected after transcardiac perfusion and fixed in 4%(v/v) PFA for an extra 2 h, then paraffin-embedded. Histology analysis was done at a 20x magnification, on whole kidney sections. Images were taken with Slide Scanner Leica, Aperio Versa 200 digital scanner and further analyzed in the Aperio ImageScope 12.43.3 software. Renal tubular damage was described based on luminal dilatation and necrosis, loss of brush border, and cast formation. The investigator was blinded to experimental conditions.</p></sec><sec id="S12"><title>PCR and qPCR</title><p id="P18">Specific primers for <italic>Glucokinase</italic> cDNA amplification from exon 1 to the mCardinal sequence are reported in <xref ref-type="supplementary-material" rid="SD7">Supp. Table 1</xref>. Briefly, was cDNA synthesized from total Trizol- Chloroform purified mRNA from isolated islets of either Gck<sup>KI/KI</sup> or WT animals. cDNA was synthesized using High-Capacity cDNA Reverse Transcription kit (Applied biosystems, Thermo-Fisher). After PCR amplification of exon 1 and exon 9, the product was migrated on a 1.0% agarose gel, the ~850bp band was excised, purified and Sanger sequenced (Genome-Quebec, Canada).</p></sec><sec id="S13"><title>Calcium imaging</title><p id="P19">Ca<sup>2+</sup> imaging was performed essentially as described (<xref ref-type="bibr" rid="R39">39</xref>; <xref ref-type="bibr" rid="R40">40</xref>) using a Zeiss LSM 900 Airyscan 2 super-resolution confocal microscope, equipped with an incubation system set at 37°C. A 40×/1.3 Apochromat oil immersion objective was employed with a frame rate of 150ms (~6Hz) with 512 x 512 px image size. 1h before imaging, islets were transferred into Krebs buffer (130 mM NaCl, 3.6 mM KCl, 1.5 mM CaCl<sub>2</sub>, 0.5 mM MgSO<sub>4</sub>, 0.5 mM NaH<sub>2</sub>PO<sub>4</sub>, 24 mM NaHCO<sub>3</sub>, 10 mM HEPES; pH 7.4), containing 3 mmol/L glucose. For Dorzagliatin (HMS5552; Abmol Biosciences) (<xref ref-type="bibr" rid="R41">41</xref>; <xref ref-type="bibr" rid="R42">42</xref>) treatment, islets were transferred to Krebs buffer with 1% DMSO and 10 μm Dorzagliatin for 1h prior to imaging. Imaging was performed at 11 mM glucose.</p></sec><sec id="S14"><title>Connectivity analysis</title><p id="P20">Analysis was performed essentially as per (<xref ref-type="bibr" rid="R39">39</xref>), with modifications. Fluorescence traces were normalized using the formula: <disp-formula id="FD1"><mml:math id="M1"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mtext>F</mml:mtext><mml:mtext>T</mml:mtext></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mtext>F</mml:mtext><mml:mrow><mml:mtext>MIN</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mtext>F</mml:mtext><mml:mrow><mml:mtext>MIN</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula></p><p id="P21">Smoothing was used to adjust Ca<sup>2+</sup> signals via a moving average filter, contributing to 1% of the total length of the Ca<sup>2+</sup> recording. Cell activity was represented in binary form, where any time point deviating &gt;20% above the baseline was considered to be active, represented by “1”. Any inactive time point, under the threshold, is represented by a “0”. The following formula was used to calculate coactivity for each cell pair: <disp-formula id="FD2"><mml:math id="M2"><mml:mrow><mml:mtext>Cij</mml:mtext><mml:mo>=</mml:mo><mml:mtext>Tij</mml:mtext><mml:mo>−</mml:mo><mml:mtext>sqr</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mtext>Ti</mml:mtext></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mtext>Tj</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p id="P22"><italic>Tij</italic> denotes the total coactivity of each cell pair. <italic>Ti</italic> and <italic>Tj</italic> are the total activity time for the two cells compared, respectively.</p><p id="P23">Cells are considered to be linked if their t-test displayed a chance (&gt;2 standard deviations i.e. p&lt;0.01) probability within a corresponding distribution of the shuffled (10,000 times) binarized observed dataset, for the analyzed cell pairs.</p><p id="P24">A topographic representation of the connectivity was plotted in MATLAB (available from: <ext-link ext-link-type="uri" xlink:href="https://www.mathworks.com-matlabcentral-fileexchange-24035-wgplot-weighted-graph-plot-a-better-version-of-gplot">https://www.mathworks.com-matlabcentral-fileexchange-24035-wgplot-weighted-graph-plot-a-better-version-of-gplot</ext-link>). Edge colors indicate the strength of the coactivity. Highly connected (“Hub”) cells were defined as those where &gt;70 % of connections had a connectivity value of &gt;0.7.</p></sec><sec id="S15"><title>Western (immuno-) blotting</title><p id="P25">Blotting was performed <italic>as per</italic> (<xref ref-type="bibr" rid="R43">43</xref>). Isolated islets were washed twice with PBS, and fast frozen on dry ice. To extract proteins, 10uL of RIPA buffer plus protease inhibitors was added to 100 islets, and samples sonicated for 3s on ice. Protein concentration was estimated by Pierce BCA protein assay (ThermoFisher). One volume of Laemmli (4x) solubilization buffer was added, followed by exposure to 95°C for 60s to denature proteins. 10μg protein per lane was loaded onto 10%(w/v) acrylamide gels. For liver, lung and heart, 10uL RIPA buffer with protease inhibitors per mg wet weight was added. Protein extract (20μg) was loaded onto each lane. After electrophoresis, proteins were transferred to PVDF membranes. Membranes were blocked with 3% BSA, TBST 1%. After 1h, membranes were incubated with primary antibody overnight at 4°xC. Membranes were washed with TBST 1% before incubation with secondary antibody (1h, room temperature). Horseradish peroxidase (HRP) chemiluminescent substrate (ECL western substrate, Thermo) was used to reveal bound antibody.</p></sec><sec id="S16"><title>Statistics</title><p id="P26">Data are expressed as mean ± SD, unless otherwise stated and significance tested by one or two-way ANOVA with Šidák or Brown-Forsythe multiple comparison tests, using GraphPad Prism 9 (GraphPad Software, San Diego, CA). <italic>P</italic> &lt; 0.05 was considered significant.</p></sec><sec id="S17"><title>Data resource and availability</title><p id="P27">All data generated or analyzed during this study are included in the published article (and its online supplementary files. Details of movies are provided in the Supp. Figure document, which includes original gel blots in <xref ref-type="supplementary-material" rid="SD1">SFig.s 8,9</xref>). Analytical scripts are provided at <ext-link ext-link-type="uri" xlink:href="https://zenodo.org/records/14042795">https://zenodo.org/records/14042795</ext-link>.</p></sec></sec><sec id="S18" sec-type="results"><title>Results</title><sec id="S19"><title>Generation of a hypomorphic <italic>Gck</italic> allele</title><p id="P28">With the initial objective of identifying beta cell subpopulations enriched for GK (which may correspond to highly connected “hub” cells) (<xref ref-type="bibr" rid="R44">44</xref>), we designed a “knock-in” construct encoding exons 3-10 of mouse <italic>Gck</italic>, followed by an internal ribosome entry site (IRES), cDNA encoding the fluorescent protein mCardinal, and a polyA sequence (Materials and Methods, <xref ref-type="fig" rid="F1">Fig. 1A,C</xref>, <xref ref-type="supplementary-material" rid="SD1">SFig. 1A</xref>). Genomic sequencing confirmed the expected integration at the <italic>Gck</italic> locus (not shown). However, and unexpectedly, an alternatively-spliced product was generated, predicted to encode a mutant protein that lacks much of the small lobe of GK (<xref ref-type="bibr" rid="R31">31</xref>).</p><p id="P29">GK protein levels in islets from wild type and mutant mice were assessed by Western (immuno-) blotting (<xref ref-type="fig" rid="F2">Fig. 2</xref>). <italic>Gck</italic> is expressed from different promoters in the liver and in the pancreatic beta cell (<xref ref-type="bibr" rid="R45">45</xref>). Consequently, the first 15 amino acids (AAs) encoded by exon 1 from the beta cell promoter differ from those of the equivalent exon encoded in the liver (<xref ref-type="bibr" rid="R6">6</xref>). The antibody deployed (Thermofisher Glucokinase Antibody PA5-15072) is raised against the first 30 AA of type 1 GK (islet). Loss of the following 16 AA (encoded by exon 2) from the epitope is thus likely to weaken or destroy recognition by the antibody of the mis-spliced isoform. This approach revealed a 30-45% and &gt;85% lowering in apparent GK immunoreactivity (~48 kDa) in islets from GK<sup>KI/+</sup> and GK<sup>KI/KI</sup> islets, respectively, <italic>versus</italic> control mice of either sex, indicating a proportionate lowering of the intact isoform 1 protein (including exons 2 and 3) (<xref ref-type="fig" rid="F2">Figure 2B</xref>). We note that, if present, the mutant is expected to be inactive, given (a) the requirement for the ATP binding sites encoded by exon 3 (<xref ref-type="bibr" rid="R6">6</xref>) and (b) the likely absence, based on structural prediction with AlphaFold (see Methods, <xref ref-type="fig" rid="F1">Fig. 1D,E</xref>, <xref ref-type="supplementary-material" rid="SD2">S.Movie1</xref>), of a properly-folded glucose-binding beta sheet in the small lobe.</p><p id="P30">No differences in immunoreactivity at this molecular weight were observed in liver extracts from WT, Gck<sup>KI/+</sup> and Gck<sup>KI/KI</sup> animals, presumably reflecting the failure of the antibody to recognise the liver isoform (<xref ref-type="supplementary-material" rid="SD1">SFig. 2</xref>).</p></sec><sec id="S20"><title>Metabolic characterisation of <italic>Gck</italic> mutant mice</title><p id="P31">Examined at 8 weeks of age, heterozygous (Gck<sup>KI/+</sup>) mice displayed normal body weight, whilst male homozygous (Gck<sup>KI/KI</sup>) animals were lighter than littermate controls (<xref ref-type="fig" rid="F3">Fig. 3A,B</xref>); a similar tendency was seen in females (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). HbA1c levels tended to be elevated, or were drastically increased, respectively, in Gck<sup>KI/+</sup> and Gck<sup>KI/KI</sup> animals <italic>versus</italic> controls (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). Fasting blood glucose (FBG) was &gt;18 mmol/L in the latter animals of either sex at eight weeks of age (males, <italic>n</italic>=7, 21.6 to&gt;33.3 mmol/L; females, <italic>n</italic>=5, 18.4-27.4 mmol/L; <xref ref-type="fig" rid="F3">Fig. 3D,F</xref>). Whereas overnight (16 h) FBG did not differ between Gck<sup>+/+</sup> and Gck<sup>KI/+</sup> mice of either sex (<xref ref-type="fig" rid="F3">Fig. 3D,E</xref>), Gck<sup>KI/+</sup> animals displayed markedly abnormal glucose tolerance, with no return to pre-infusion levels after 90 min. Blood glucose levels after 6 h fasting were higher in Gck<sup>KI/+</sup> <italic>versus</italic> WT mice (<xref ref-type="fig" rid="F3">Fig. 3F,G</xref>,). Insulin sensitivity did not differ between genotypes, after correction for FBG (<xref ref-type="fig" rid="F3">Fig. 3F</xref> <italic>insets</italic>, <xref ref-type="fig" rid="F3">Fig. 3G</xref>).</p><p id="P32">Measured in batch incubations, glucose-stimulated insulin secretion (GSIS) from male islets was lowered by ~50 % in Gck<sup>KI/+</sup> versus controls, and eliminated in homozygous Gck<sup>KI/KI</sup> islets (<xref ref-type="fig" rid="F3">Fig. 3H</xref>). In females, GSIS was unaffected in Gck<sup>KI/+</sup> but eliminated in Gck<sup>KI/KI</sup> islets (<xref ref-type="fig" rid="F3">Fig. 3H</xref>).</p><p id="P33">Whilst also unaltered in Gck<sup>KI/+</sup> mice <italic>versus</italic> controls, beta cell mass was substantially (~65% in males, ~50 % in females) lowered in Gck<sup>KI/KI</sup> animals (<xref ref-type="supplementary-material" rid="SD1">SFig. 3</xref>). Conversely, alpha cell numbers were markedly increased in Gck<sup>KI/KI</sup> mice (~2-fold in both sexes; <xref ref-type="supplementary-material" rid="SD1">SFig. 3</xref>). Consequently, the beta:alpha cell ratio fell from ~10:1.0 in wildtype to ~1.0:1.0 in Gck<sup>KI/KI</sup> pancreata.</p><p id="P34">Consistent with frank diabetes, ketone levels tended to be, or were significantly, increased in male and female Gck<sup>KI/KI</sup> animals <italic>versus</italic> controls, respectively (<xref ref-type="fig" rid="F3">Fig. 3I</xref>). Moreover, in the kidney, homozygous Gck<sup>KI/KI</sup> mice of either sex displayed clear tubular alterations compared to heterozygous Gck<sup>KI/+</sup> and control mice (<xref ref-type="supplementary-material" rid="SD1">SFig. 4</xref>; <xref ref-type="supplementary-material" rid="SD8">Supp. Table 2</xref>).</p></sec><sec id="S21"><title>Ca<sup>2+</sup> dynamics and intercellular connectivity</title><p id="P35">The above findings suggested that defects may exist in intracellular glucose handling or signalling in mutant beta cells. To explore this possibility, we studied glucose-regulated intracellular Ca<sup>2+</sup> dynamics and cell-cell connectivity in isolated islets using high speed confocal imaging (<xref ref-type="fig" rid="F4">Fig.4A</xref>) (<xref ref-type="bibr" rid="R44">44</xref>). To ensure that Ca<sup>2+</sup> was measured exclusively in beta cells, mice were bred to animals carrying Ins1<italic>Cre</italic> alleles (<xref ref-type="bibr" rid="R46">46</xref>) and STOP-Flox alleles of the genetic Ca<sup>2+</sup> sensor, GCaMP6f (<xref ref-type="bibr" rid="R34">34</xref>). Male animals carrying wild type <italic>Gck</italic> alleles displayed robust responses to stimulation with 11 mM glucose, and a high degree of connectivity (<xref ref-type="fig" rid="F4">Fig. 4B-E</xref>; <xref ref-type="supplementary-material" rid="SD3">SMovie 2</xref>,<xref ref-type="supplementary-material" rid="SD4">3</xref>). These responses were significantly weakened in Gck<sup>KI/+</sup> mice and almost completely eliminated in Gck<sup>KI/KI</sup> animals. Similar behaviour was seen in islets from animals of both sexes, though the Ca<sup>2+</sup> responses (area under the curve, AUC) were lower in females than males (<xref ref-type="fig" rid="F4">Fig. 4, E-G</xref> <xref ref-type="supplementary-material" rid="SD1">SFig. 6</xref>). Remarkably, these responses were fully normalized with dorzagliatin in Gck<sup>KI/+</sup> mice of both sexes <xref ref-type="fig" rid="F4">Fig.4F,G</xref>, <xref ref-type="supplementary-material" rid="SD1">SFig. 6</xref>, <xref ref-type="supplementary-material" rid="SD5">SMovie 4</xref>,<xref ref-type="supplementary-material" rid="SD6">5</xref>), but barely affected in Gck<sup>KI/KI</sup> mice. Nevertheless, a subset of female Gck<sup>KI/KI</sup> islets showed detectable Ca<sup>2+</sup> transients in response to glucose stimulation in the presence of dorzagliatin (<xref ref-type="fig" rid="F4">Fig. 4, F,G</xref>).</p></sec><sec id="S22"><title>Responses of wildtype and Gck<sup>KI/+</sup> mice to GKA and incretin <italic>in vivo</italic></title><p id="P36">Given the findings above, we next explored the effects of dorzagliatin <italic>in vivo</italic> during intraperitoneal glucose tolerance tests (IPGTT), in the presence or absence of the GLP-1 receptor agonist, exendin-4.</p><p id="P37">Examined in wildtype mice of either sex, acute injection of dorzagliatin or exendin-4 alone exerted only minor effects on glucose tolerance, which did not reach statistical significance (<xref ref-type="fig" rid="F5">Fig. 5A-D</xref>). On the other hand, in wildtype male (but not female) mice, co-injection of dorzagliatin markedly potentiated the action of exendin-4 (<xref ref-type="fig" rid="F5">Fig. 5A-D</xref>).</p><p id="P38">In male heterozygous Gck<sup>KI/+</sup> mice, exendin-4 alone, but not dorzagliatin, improved glucose tolerance, whilst the combination of exendin-4 and dorzagliatin profoundly lowered glucose excursions to levels comparable to those in wildtype mice (<xref ref-type="fig" rid="F5">Fig. 5, A,C</xref>). In female Gck<sup>KI/+</sup> mice, dorzagliatin again exerted no effect when administered alone, whereas exendin-4 markedly improved glucose tolerance. No additional effect was observed of co-injecting dorzagliatin and exendin-4 (<xref ref-type="fig" rid="F5">Fig. 5 B,D</xref>).</p><p id="P39">Combining data from both sexes, we noted that neither drug, alone or in combination, significantly affected glycemia in homozygous (Gck<sup>KI/KI</sup>) animals (<xref ref-type="fig" rid="F5">Fig.5E</xref>).</p></sec><sec id="S23"><title>Effects of incretin and GKA on glucose-stimulated insulin secretion</title><p id="P40">Explored <italic>in vivo</italic> during IPGTTs, glucose-induced increases in circulating insulin tended to be potentiated by incretin in male, but not female, Gck<sup>+/+</sup> and Gck<sup>KI/+</sup> mice (<xref ref-type="supplementary-material" rid="SD1">SFig. 6</xref>). Since inter-animal variation was large in these experiments, we examined the potential interaction between the GKA and incretin on insulin secretion <italic>ex vivo</italic>. In islets isolated from wildtype male mice, neither dorzagliatin nor exendin-4 significantly affected insulin secretion stimulated by 17 mmol/L glucose (<xref ref-type="fig" rid="F6">Fig. 6A</xref>). In contrast, the combination of dorzagliatin and exendin-4 stimulated hormone release 2.0-2.5-fold. In islets from male Gck<sup>KI/+</sup> mice (<xref ref-type="fig" rid="F6">Fig. 6A</xref>), dorzagliatin alone tended to increase secretion, whilst exendin-4 alone caused a ~3-fold increase in hormone release. The effect of incretin was further augmented by dorzagliatin (~5-fold increase <italic>versus</italic> 17 mmol/L glucose alone). Qualitatively similar results were obtained in female wildtype mice (<xref ref-type="fig" rid="F6">Fig. 6B</xref>). In female Gck<sup>KI/+</sup> islets, the effects of dorzagliatin or exendin-4, whether administered alone or together, were weaker than those in Gck<sup>KI/+</sup> males (<xref ref-type="fig" rid="F6">Fig. 6B</xref> <italic>versus</italic> <xref ref-type="fig" rid="F6">Fig.6A</xref>).</p><p id="P41">When data from both sexes were pooled, exendin-4 was found to potentiate glucose-stimulated insulin secretion in Gck<sup>KI/+</sup> islets, an action further enhanced by dorzagliatin (<xref ref-type="fig" rid="F6">Fig. 6C</xref>). Similar, albeit nonsignificant, tendencies were observed in wildtype and in Gck<sup>KI/KI</sup> islets (<xref ref-type="fig" rid="F6">Fig. 6C</xref>).</p></sec></sec><sec id="S24" sec-type="discussion"><title>Discussion</title><sec id="S25"><title>Novel models of “glucokinase” diabetes</title><p id="P42">We describe here novel mouse models of <italic>GCK</italic>-MODY and <italic>GCK</italic>-PNDM, and explore the potentiation of glucose-stimulated insulin secretion by a glucokinase activator and incretin in each case.</p><p id="P43">More than 600 variants are associated with human <italic>GCK</italic>-MODY, with eight identified in <italic>GCK</italic>-PNDM (<xref ref-type="bibr" rid="R47">47</xref>). The latter vary in their effects on GK activity or stability, and have broadly proportional clinical impacts (<xref ref-type="bibr" rid="R21">21</xref>). Whilst homozygosity for mutants with nearzero activity is usually implicated in PNDM, compound heterozygosity for an inactivating (e.g. (intervening sequence 8 [IVS8] + 2T→G) and hypomorphic (G264S) variant (<xref ref-type="bibr" rid="R16">16</xref>) can also drive neonatal diabetes. On the other hand, milder mutations e.g. G223S, L315H, with relative activities of 0.25 and 0.89, respectively (<xref ref-type="bibr" rid="R48">48</xref>), lead to <italic>GCK</italic>-MODY. Interestingly in the context of the present study, Osbak <italic>et al</italic> have speculated that milder <italic>GCK</italic> mutations in <italic>GCK</italic>-PNDM e.g. R397L (<xref ref-type="bibr" rid="R16">16</xref>; <xref ref-type="bibr" rid="R49">49</xref>) may be more responsive to GKA than those leading to more complete inactivation e.g, T168A (<xref ref-type="bibr" rid="R50">50</xref>).</p><p id="P44">The hypomorphic <italic>Gck</italic> allele described here was originally designed to preserve an intact glucokinase protein, whilst independently expressing, from the same transcript, the fluorescent reporter mCardinal. Instead, an unexpected splicing event eliminated exons 2 and 3 (encoded by the host genome) and led to the fusion of exon 1 to exon 4, derived from the introduced <italic>Gck</italic> cDNA (exons 4-11). The aberrantly-spliced transcript is predicted to produce an inactive protein, lacking much of the ATP- and glucose-binding catalytic domain of the smaller lobe (<xref ref-type="bibr" rid="R31">31</xref>). It is also possible that the variant transcript fails to produce any protein product at all. Our Western blotting approach was unable to distinguish between these possibilities, since the product of the aberrantly-spliced variant is unlikely to be detected by the N-terminal targeting antibody used (Results).</p><p id="P45">In any case, limited correct splicing appears to produce low levels of the active, wildtype protein (10-15% of normal values). Consequently, the Gck<sup>KI</sup> allele provides a convenient model of inactivating <italic>GCK</italic> mutations that affect the kinetic properties of GK as well as of variants that lead to thermal instability and protein degradation (<xref ref-type="bibr" rid="R51">51</xref>).</p><p id="P46">Enzymatic measurements of GK were not performed since these require beta cell purification to exclude contamination from hexokinases I-III abundant in other cell types (<xref ref-type="bibr" rid="R52">52</xref>). Nevertheless, the metabolic features of homozygous <italic>Gck</italic><sup>KI/Ki</sup> mice (<xref ref-type="fig" rid="F3">Fig. 3</xref>,<xref ref-type="fig" rid="F5">5</xref>), studies of glucose regulated Ca<sup>2+</sup> dynamics (<xref ref-type="fig" rid="F4">Fig. 4</xref>; <xref ref-type="supplementary-material" rid="SD1">SFig 5</xref>) and insulin secretion (<xref ref-type="fig" rid="F3">Fig.s 3</xref>,<xref ref-type="fig" rid="F6">6</xref>) are consistent with near-complete elimination of GK activity from the beta (and other pancreatic endocrine) cells. The persistence of residual glucokinase activity in beta cells likely explains why homozygous Gck<sup>KI/KI</sup> mice survive into adulthood, in contrast with models of complete <italic>Gck</italic> inactivation (<xref ref-type="bibr" rid="R23">23</xref>) (see Introduction). Of note, the metabolic phenotype of heterozygous (Gck<sup>KI/+</sup>) mice was almost indistinguishable from that of previous models involving complete inactivation of a single allele, and thus is compatible with loss of 40-45% of GK activity. Ca<sup>2+</sup> imaging revealed the expected defects in glucose signaling in both Gck<sup>KI/+</sup> and Gck<sup>KI/KI</sup> islets, and the expected rescue of these deficits by dorzagliatin in the former, reflecting the activation of the remaining glucokinase. Whilst the glucokinase activator was largely inactive in male Gck<sup>KI/KI</sup> islets, as anticipated, 10-30 % of islets displayed responses to dorzagliatin in females (<xref ref-type="fig" rid="F4">Fig. 4F,G</xref>). Interestingly, these findings suggest that correctly spliced, active, GK may be restricted to a subset of Gck<sup>KI/KI</sup> islets.</p><p id="P47">Our observation of lowered beta cell mass in homozygous mice aligns with earlier studies in glucokinase-deficient mice (<xref ref-type="bibr" rid="R53">53</xref>). Less expected was the increase in alpha cell mass in Gck<sup>KI/KI</sup> islets, suggesting that GK activity plays a role in suppressing alpha cell expansion, in addition to inhibiting glucagon secretion (<xref ref-type="bibr" rid="R54">54</xref>). Extrapolated to humans, these findings raise the intriguing possibility that elevated glucagon levels may aggravate hyperglycemia in <italic>GCK</italic>-PNDM.</p><p id="P48">We note that, in addition to islets and liver, glucokinase is expressed in several brain nuclei, including the hypothalamus, pituitary and brain stem (<xref ref-type="bibr" rid="R33">33</xref>), as well as in intestinal L-cells (<xref ref-type="bibr" rid="R55">55</xref>). As such, the phenotypes of Gck<sup>KI/+</sup> and Gck<sup>KI/KI</sup> mice may in part reflect actions on these cell types.</p></sec><sec id="S26"><title>Sex-dependent additive effects of dorzagliatin and incretin on glucose tolerance and insulin secretion</title><p id="P49">Previous work with earlier-generation GKAs (e.g. the AstraZeneca molecule, GKA50) (<xref ref-type="bibr" rid="R56">56</xref>), reported a marked left-shift in the response to glucose in both mouse and human islets. Under the conditions used here, involving high glucose concentrations in both settings, dorzagliatin alone elicited minimal effects either <italic>in vivo</italic> on glucose tolerance (<xref ref-type="fig" rid="F5">Fig 5 C,D,E</xref>), or on glucose-stimulated insulin secretion (<xref ref-type="fig" rid="F6">Fig. 6A,B</xref>) both in wildtype and Gck<sup>KI/+</sup> mice. Nevertheless, the GKA markedly potentiated the effects of exendin-4 on glucose-stimulated insulin secretion both <italic>in vivo</italic> (<xref ref-type="fig" rid="F5">Fig. 5C</xref>) and <italic>in vitro</italic> (<xref ref-type="fig" rid="F6">Fig. 6A</xref>), an effect most dramatic in heterozygous male mice. The mechanisms underlying this apparent sexual dimorphism in drug responses remain unclear.</p></sec><sec id="S27" sec-type="conclusions"><title>Conclusions</title><p id="P50">We describe here new mouse models of <italic>GCK</italic>-MODY and <italic>GCK</italic>-PNDM, which may be valuable for future drug screens as well as studies of diabetes complications, including nephropathy. We demonstrate the remarkable efficacy in the former of combining a GKA with a GLP-1R agonist, likely reflecting a requirement for beta cell glucose metabolism for incretin action (<xref ref-type="bibr" rid="R28">28</xref>). Our findings suggest the potential therapeutic utility of this drug combination in selected <italic>GCK</italic>-MODY or <italic>GCK</italic>-PNDM patients.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>All Supp Figures</label><media xlink:href="EMS200057-supplement-All_Supp_Figures.pdf" mimetype="application" mime-subtype="pdf" id="d62aAcEbB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>SMovie 1</label><media xlink:href="EMS200057-supplement-SMovie_1.mpg" mimetype="video" mime-subtype="mpeg" id="d62aAcEcB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>SMovie 2</label><media xlink:href="EMS200057-supplement-SMovie_2.mpg" mimetype="video" mime-subtype="mpeg" id="d62aAcEdB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>SMovie 3</label><media xlink:href="EMS200057-supplement-SMovie_3.mpg" mimetype="video" mime-subtype="mpeg" id="d62aAcEeB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>SMovie 4</label><media xlink:href="EMS200057-supplement-SMovie_4.mpg" mimetype="video" mime-subtype="mpeg" id="d62aAcEfB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><label>SMovie 5</label><media xlink:href="EMS200057-supplement-SMovie_5.mpg" mimetype="video" mime-subtype="mpeg" id="d62aAcEgB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD7"><label>Supp. Tabe 1</label><media xlink:href="EMS200057-supplement-Supp__Tabe_1.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d62aAcEhB" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD8"><label>Supp. Table 2</label><media xlink:href="EMS200057-supplement-Supp__Table_2.pdf" mimetype="application" mime-subtype="pdf" id="d62aAcEiB" position="anchor"/></supplementary-material></sec></body><back><ack id="S28"><title>Acknowledgements</title><p>We thank the CRCHUM Cell Imaging, Animal and Cellular Physiology Facilities for their assistance and Jannick Bonenfant (UdeM) for help with imaging experiments. We are grateful to Drs Khalil Boudaydan, Demetra Rodaros and Thierry Alquier (CRCHUM) for fluorescence measurements in liver and brain sections.</p><sec id="S29"><title>Funding</title><p>G.A.R. was supported by a Wellcome Trust Investigator Award (WT212625/Z/18/Z), MRC Programme grant (MR/R022259/1), Diabetes UK (BDA 16/0005485) and NIH-NIDDK (R01DK135268) project grants, a CIHR-JDRF Team grant (CIHR-IRSC TDP-186358 and JDRF 4-SRA-2023-1182-S-N), CRCHUM start-up funds, and an Innovation Canada John R. Evans Leader Award (CFI 42649). LD was support by a CIHR/IRSC Post-doctoral Fellowship (#489982), PC and GO by Fonds de Recherche du Quebec, Nature and Technology Fellowships (#353239, #333916).</p></sec></ack><fn-group><fn id="FN1" fn-type="conflict"><p id="P51"><bold>Duality of Interest</bold></p><p id="P52">G.A.R. has received grant funding from, and is a consultant for, Sun Pharmaceuticals Inc. No other potential conflicts of interest relevant to this article were reported.</p></fn><fn id="FN2" fn-type="con"><p id="P53"><bold>Author contributions</bold></p><p id="P54">GAR and MOH conceived the project. GAR designed the studies, supervised the project and wrote the manuscript with input from all authors. SS and LD performed <italic>in vivo</italic> metabolic analyses, and studies of Ca<sup>2+</sup> dynamics, alongside GO and KD. KB, DR, WT and TA performed histological studies and immunohistochemistry of liver and brain sections. IK, JT, FM and MJH analysed kidney sections with PC, who performed <italic>in vitro</italic> insulin secretion analyses with RM and quantified beta/alpha cell mass. LD, KD, RM and SS performed analysis of alternative splicing, and LD structural modelling with AlphaFold.</p><p id="P55">G.A.R. serves as guarantor of the study.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="web"><collab>International Diabetes Federation</collab><year>2023</year><comment><ext-link ext-link-type="uri" xlink:href="https://idf.org/news/diabetes-now-affects-one-in-10-adults-worldwide/">https://idf.org/news/diabetes-now-affects-one-in-10-adults-worldwide/</ext-link></comment></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeedi</surname><given-names>P</given-names></name><name><surname>Petersohn</surname><given-names>I</given-names></name><name><surname>Salpea</surname><given-names>P</given-names></name><name><surname>Malanda</surname><given-names>B</given-names></name><name><surname>Karuranga</surname><given-names>S</given-names></name><name><surname>Unwin</surname><given-names>N</given-names></name><name><surname>Colagiuri</surname><given-names>S</given-names></name><name><surname>Guariguata</surname><given-names>L</given-names></name><name><surname>Mótala</surname><given-names>AA</given-names></name><name><surname>Ogurtsova</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>157</volume><elocation-id>107843</elocation-id><pub-id pub-id-type="pmid">31518657</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coore</surname><given-names>HG</given-names></name><name><surname>Randle</surname><given-names>PJ</given-names></name></person-group><article-title>Inhibition of glucose phosphorylation by mannoheptulose</article-title><source>Biochemical Journal</source><year>1964</year><volume>91</volume><fpage>56</fpage><lpage>59</lpage><pub-id pub-id-type="pmcid">PMC1202814</pub-id><pub-id pub-id-type="pmid">5319361</pub-id><pub-id pub-id-type="doi">10.1042/bj0910056</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grodsky</surname><given-names>GM</given-names></name><name><surname>Batts</surname><given-names>AA</given-names></name><name><surname>Bennett</surname><given-names>LL</given-names></name><name><surname>Vcella</surname><given-names>C</given-names></name><name><surname>McWilliams</surname><given-names>NB</given-names></name><name><surname>Smith</surname><given-names>DF</given-names></name></person-group><article-title>Effects of carbohydrates on secretion of insulin from isolated rat pancreas</article-title><source>Am J Physiol</source><year>1963</year><volume>205</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">14060797</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meglasson</surname><given-names>MD</given-names></name><name><surname>Matschinsky</surname><given-names>FM</given-names></name></person-group><article-title>Pancreatic islet glucose metabolism and regulation of insulin secretion</article-title><source>Diabetes/Metabolism Reviews</source><year>1986</year><volume>2</volume><fpage>163</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">2943567</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>lynedjian</surname><given-names>PB</given-names></name></person-group><article-title>Mammalian glucokinase and its gene</article-title><source>BiochemJ</source><year>1993</year><volume>293</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmcid">PMC1134312</pub-id><pub-id pub-id-type="pmid">8392329</pub-id><pub-id pub-id-type="doi">10.1042/bj2930001</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matschinsky</surname><given-names>FM</given-names></name></person-group><article-title>Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm</article-title><source>Diabetes</source><year>1996</year><volume>45</volume><fpage>223</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">8549869</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rorsman</surname><given-names>P</given-names></name><name><surname>Ashcroft</surname><given-names>FM</given-names></name></person-group><article-title>Pancreatic beta-Cell Electrical Activity and Insulin Secretion: Of Mice and Men</article-title><source>Physiol Rev</source><year>2018</year><volume>98</volume><fpage>117</fpage><lpage>214</lpage><pub-id pub-id-type="pmcid">PMC5866358</pub-id><pub-id pub-id-type="pmid">29212789</pub-id><pub-id pub-id-type="doi">10.1152/physrev.00008.2017</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>GA</given-names></name><name><surname>Sidarala</surname><given-names>V</given-names></name><name><surname>Kaufman</surname><given-names>BA</given-names></name><name><surname>Soleimanpour</surname><given-names>SA</given-names></name></person-group><article-title>Mitochondrial metabolism and dynamics in pancreatic beta cell glucose sensing</article-title><source>Biochem J</source><year>2023</year><volume>480</volume><fpage>773</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">37284792</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henquin</surname><given-names>JC</given-names></name></person-group><article-title>Regulation of insulin secretion: a matter of phase control and amplitude modulation</article-title><source>Diabetologia</source><year>2009</year><volume>52</volume><fpage>739</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">19288076</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prentki</surname><given-names>M</given-names></name><name><surname>Madiraju</surname><given-names>SR</given-names></name></person-group><article-title>Glycerolipid/free fatty acid cycle and islet beta-cell function in health, obesity and diabetes</article-title><source>MolCell Endocrinol</source><year>2012</year><volume>353</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">22108437</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>HJ</given-names></name><name><surname>Pouli</surname><given-names>AE</given-names></name><name><surname>Ainscow</surname><given-names>EK</given-names></name><name><surname>Jouaville</surname><given-names>LS</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name><name><surname>Rutter</surname><given-names>GA</given-names></name></person-group><article-title>Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells. Potential role for strategically located mitochondria</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>13281</fpage><lpage>13291</lpage><pub-id pub-id-type="pmid">10224088</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>HR</given-names></name><name><surname>Ho</surname><given-names>T</given-names></name><name><surname>Potapenko</surname><given-names>E</given-names></name><name><surname>Sdao</surname><given-names>SM</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Lewandowski</surname><given-names>SL</given-names></name><name><surname>VanDeusen</surname><given-names>HR</given-names></name><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Cardone</surname><given-names>RL</given-names></name><name><surname>Prentki</surname><given-names>M</given-names></name><name><surname>Kibbey</surname><given-names>RG</given-names></name><etal/></person-group><article-title>ß-cell deletion of the PKml and PKm2 isoforms of pyruvate kinase in mice reveals their essential role as nutrient sensors for the K(ATP) channel</article-title><source>Elife</source><year>2022</year><volume>11</volume><pub-id pub-id-type="pmcid">PMC9444242</pub-id><pub-id pub-id-type="pmid">35997256</pub-id><pub-id pub-id-type="doi">10.7554/eLife.79422</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>GA</given-names></name><name><surname>Sweet</surname><given-names>IR</given-names></name></person-group><article-title>Glucose Regulation of ß-Cell KATP Channels: Is a New Model Needed?</article-title><source>Diabetes</source><year>2024</year><volume>73</volume><fpage>849</fpage><lpage>855</lpage><pub-id pub-id-type="pmcid">PMC11109788</pub-id><pub-id pub-id-type="pmid">38768365</pub-id><pub-id pub-id-type="doi">10.2337/dbi23-0031</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>De León</surname><given-names>DD</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name></person-group><chapter-title>Permanent Neonatal Diabetes Mellitus</chapter-title><person-group person-group-type="editor"><name><surname>Adam</surname><given-names>MP</given-names></name><name><surname>Feldman</surname><given-names>J</given-names></name><name><surname>Mirzaa</surname><given-names>GM</given-names></name><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Wallace</surname><given-names>SE</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name></person-group><source>GeneReviews(®)</source><publisher-loc>Seattle (WA)</publisher-loc><publisher-name>University of Washington, SeattleCopyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle</publisher-name><year>1993</year><comment>All rights reserved</comment></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njølstad</surname><given-names>PR</given-names></name><name><surname>Sagen</surname><given-names>JV</given-names></name><name><surname>Bjørkhaug</surname><given-names>L</given-names></name><name><surname>Odili</surname><given-names>S</given-names></name><name><surname>Shehadeh</surname><given-names>N</given-names></name><name><surname>Bakry</surname><given-names>D</given-names></name><name><surname>Sarici</surname><given-names>SU</given-names></name><name><surname>Alpay</surname><given-names>F</given-names></name><name><surname>Moines</surname><given-names>J</given-names></name><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Søvik</surname><given-names>O</given-names></name><etal/></person-group><article-title>Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>2854</fpage><lpage>2860</lpage><pub-id pub-id-type="pmid">14578306</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Njølstad</surname><given-names>PR</given-names></name><name><surname>Søvik</surname><given-names>O</given-names></name><name><surname>Cuesta-Muñoz</surname><given-names>A</given-names></name><name><surname>Bjørkhaug</surname><given-names>L</given-names></name><name><surname>Massa</surname><given-names>O</given-names></name><name><surname>Barbetti</surname><given-names>F</given-names></name><name><surname>Undlien</surname><given-names>DE</given-names></name><name><surname>Shiota</surname><given-names>C</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Matschinsky</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Neonatal diabetes mellitus due to complete glucokinase deficiency</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>1588</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">11372010</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durmaz</surname><given-names>E</given-names></name><name><surname>Flanagan</surname><given-names>S</given-names></name><name><surname>Berdeli</surname><given-names>A</given-names></name><name><surname>Semiz</surname><given-names>S</given-names></name><name><surname>Akcurin</surname><given-names>S</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Bircan</surname><given-names>I</given-names></name></person-group><article-title>Variability in the age at diagnosis of diabetes in two unrelated patients with a homozygous glucokinase gene mutation</article-title><source>J Pediatr Endocrinol Metab</source><year>2012</year><volume>25</volume><fpage>805</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">23155716</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vionnet</surname><given-names>N</given-names></name><name><surname>Stoffel</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>I</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Bell</surname><given-names>GL</given-names></name><name><surname>Zouali</surname><given-names>H</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Velho</surname><given-names>G</given-names></name><name><surname>Iris</surname><given-names>F</given-names></name><name><surname>Passa</surname><given-names>P</given-names></name></person-group><article-title>Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>721</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">1570017</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoffel</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Lucassen</surname><given-names>AM</given-names></name><name><surname>Page</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>JI</given-names></name><name><surname>Bell</surname><given-names>GL</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name><name><surname>Wainscoat</surname><given-names>JS</given-names></name></person-group><article-title>Missense glucokinase mutation in maturity-onset diabetes of the young and mutation screening in late-onset diabetes</article-title><source>Nat Genet</source><year>1992</year><volume>2</volume><fpage>153</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">1303265</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gersing</surname><given-names>S</given-names></name><name><surname>Cagiada</surname><given-names>M</given-names></name><name><surname>Gebbia</surname><given-names>M</given-names></name><name><surname>Gjesing</surname><given-names>AP</given-names></name><name><surname>Coté</surname><given-names>AG</given-names></name><name><surname>Seesankar</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Tabet</surname><given-names>D</given-names></name><name><surname>Weile</surname><given-names>J</given-names></name><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Gloyn</surname><given-names>AL</given-names></name><etal/></person-group><article-title>A comprehensive map of human glucokinase variant activity</article-title><source>Genome Biol</source><year>2023</year><volume>24</volume><fpage>97</fpage><pub-id pub-id-type="pmcid">PMC10131484</pub-id><pub-id pub-id-type="pmid">37101203</pub-id><pub-id pub-id-type="doi">10.1186/s13059-023-02935-8</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirzhner</surname><given-names>A</given-names></name><name><surname>Barak</surname><given-names>O</given-names></name><name><surname>Vaisbuch</surname><given-names>E</given-names></name><name><surname>Zornitzki</surname><given-names>T</given-names></name><name><surname>Schiller</surname><given-names>T</given-names></name></person-group><article-title>The Challenges of Treating Glucokinase MODY during Pregnancy: A Review of Maternal and Fetal Outcomes</article-title><source>Int J Environ Res Public Health</source><year>2022</year><volume>19</volume><pub-id pub-id-type="pmcid">PMC9141824</pub-id><pub-id pub-id-type="pmid">35627517</pub-id><pub-id pub-id-type="doi">10.3390/ijerph19105980</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu Aqel</surname><given-names>Y</given-names></name><name><surname>Alnesf</surname><given-names>A</given-names></name><name><surname>Aigha</surname><given-names>II</given-names></name><name><surname>Islam</surname><given-names>Z</given-names></name><name><surname>Kolatkar</surname><given-names>PR</given-names></name><name><surname>Teo</surname><given-names>A</given-names></name><name><surname>Abdelalim</surname><given-names>EM</given-names></name></person-group><article-title>Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis</article-title><source>Cell Mol Biol Lett</source><year>2024</year><volume>29</volume><fpage>120</fpage><pub-id pub-id-type="pmcid">PMC11382428</pub-id><pub-id pub-id-type="pmid">39245718</pub-id><pub-id pub-id-type="doi">10.1186/s11658-024-00640-3</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bali</surname><given-names>D</given-names></name><name><surname>Svetlanov</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>FuscoDeMane</surname><given-names>D</given-names></name><name><surname>Leiser</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Barzilai</surname><given-names>N</given-names></name><name><surname>Surana</surname><given-names>M</given-names></name><name><surname>Hou</surname><given-names>H</given-names></name><name><surname>Fleischer</surname><given-names>N</given-names></name><name><surname>DePinho</surname><given-names>R</given-names></name><etal/></person-group><article-title>Animal model for maturity-onset diabetes of the young generated by disruption of the mouse glucokinase gene</article-title><source>Journal of Biological Chemistry</source><year>1995</year><volume>270</volume><fpage>21464</fpage><lpage>21467</lpage><pub-id pub-id-type="pmid">7665557</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grupe</surname><given-names>A</given-names></name><name><surname>Hultgren</surname><given-names>B</given-names></name><name><surname>Ryan</surname><given-names>A</given-names></name><name><surname>Yan Hui</surname><given-names>M</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name></person-group><article-title>Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">7553875</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name><name><surname>Niswender</surname><given-names>KD</given-names></name><name><surname>Jetton</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Moates</surname><given-names>JM</given-names></name><name><surname>Shelton</surname><given-names>KD</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name><name><surname>Cherrington</surname><given-names>AD</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name></person-group><article-title>Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase</article-title><source>JBiolChem</source><year>1999</year><volume>274</volume><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">9867845</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Sakura</surname><given-names>H</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Iwamoto</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Kasai</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Ueda</surname><given-names>O</given-names></name><name><surname>Kamada</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>30253</fpage><lpage>30256</lpage><pub-id pub-id-type="pmid">8530440</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Müller</surname><given-names>TD</given-names></name></person-group><article-title>Incretin hormones and type 2 diabetes</article-title><source>Diabetologia</source><year>2023</year><volume>66</volume><fpage>1780</fpage><lpage>1795</lpage><pub-id pub-id-type="pmcid">PMC10474001</pub-id><pub-id pub-id-type="pmid">37430117</pub-id><pub-id pub-id-type="doi">10.1007/s00125-023-05956-x</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>D</given-names></name><name><surname>Dsouza</surname><given-names>VS</given-names></name><name><surname>Al-Mulla</surname><given-names>F</given-names></name><name><surname>Al Madhoun</surname><given-names>A</given-names></name></person-group><article-title>New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes Treatment</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><pub-id pub-id-type="pmcid">PMC10779250</pub-id><pub-id pub-id-type="pmid">38203742</pub-id><pub-id pub-id-type="doi">10.3390/ijms25010571</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>CKP</given-names></name><name><surname>Tsoi</surname><given-names>STF</given-names></name><name><surname>Fan</surname><given-names>B</given-names></name><name><surname>Poon</surname><given-names>E</given-names></name><name><surname>Luk</surname><given-names>AOY</given-names></name><name><surname>Ma</surname><given-names>RCW</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes</article-title><source>Diabetes</source><year>2023</year><volume>72</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="pmcid">PMC9871194</pub-id><pub-id pub-id-type="pmid">36342518</pub-id><pub-id pub-id-type="doi">10.2337/db22-0708</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamata</surname><given-names>K</given-names></name><name><surname>Mitsuya</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Eiki</surname><given-names>J</given-names></name><name><surname>Nagata</surname><given-names>Y</given-names></name></person-group><article-title>Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase</article-title><source>Structure</source><year>2004</year><volume>12</volume><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">15016359</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ammirati</surname><given-names>MJ</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Knafels</surname><given-names>JD</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Greasley</surname><given-names>SE</given-names></name><name><surname>Pfefferkorn</surname><given-names>JA</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name></person-group><article-title>Insights into mechanism of glucokinase activation: observation of multiple distinct protein conformations</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>13598</fpage><lpage>13610</lpage><pub-id pub-id-type="pmcid">PMC3340189</pub-id><pub-id pub-id-type="pmid">22298776</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M111.274126</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>RM</given-names></name><name><surname>Tompkins</surname><given-names>LS</given-names></name><name><surname>Brooks</surname><given-names>HL</given-names></name><name><surname>Dunn-Meynell</surname><given-names>AA</given-names></name><name><surname>Levin</surname><given-names>BE</given-names></name></person-group><article-title>Localization of glucokinase gene expression in the rat brain</article-title><source>Diabetes</source><year>2000</year><volume>49</volume><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">10905475</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>V</given-names></name><name><surname>Silva</surname><given-names>LS</given-names></name><name><surname>Suba</surname><given-names>S</given-names></name><name><surname>Georgiadou</surname><given-names>E</given-names></name><name><surname>Mousavy Gharavy</surname><given-names>SN</given-names></name><name><surname>khtar</surname><given-names>N</given-names></name><name><surname>artin-Alonso</surname><given-names>A</given-names></name><name><surname>aboriau</surname><given-names>DCA</given-names></name><name><surname>othery</surname><given-names>SM</given-names></name><name><surname>tylianides</surname><given-names>T</given-names></name><name><surname>arrat</surname><given-names>G</given-names></name><etal/></person-group><article-title>Leader beta cells coordinate Ca2+ dynamics across pancreatic islets in vivo</article-title><source>Nat Metab</source><year>2019</year><volume>1</volume><fpage>615</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">32694805</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinegger</surname><given-names>M</given-names></name><name><surname>Söding</surname><given-names>J</given-names></name></person-group><article-title>Clustering huge protein sequence sets in linear time</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><elocation-id>2542</elocation-id><pub-id pub-id-type="pmcid">PMC6026198</pub-id><pub-id pub-id-type="pmid">29959318</pub-id><pub-id pub-id-type="doi">10.1038/s41467-018-04964-5</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akalestou</surname><given-names>E</given-names></name><name><surname>Suba</surname><given-names>K</given-names></name><name><surname>Lopez-Noriega</surname><given-names>L</given-names></name><name><surname>Georgiadou</surname><given-names>E</given-names></name><name><surname>Chabosseau</surname><given-names>P</given-names></name><name><surname>Gallie</surname><given-names>A</given-names></name><name><surname>Wretlind</surname><given-names>A</given-names></name><name><surname>Quigley</surname><given-names>C</given-names></name><name><surname>Leclerc</surname><given-names>I</given-names></name><name><surname>Salem</surname><given-names>V</given-names></name><name><surname>Rutter</surname><given-names>GA</given-names></name></person-group><article-title>Intravital imaging of islet Ca(2+) dynamics reveals enhanced ×ý cell connectivity after bariatric surgery in mice</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><elocation-id>5165</elocation-id><pub-id pub-id-type="pmcid">PMC8397709</pub-id><pub-id pub-id-type="pmid">34453049</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-25423-8</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravier</surname><given-names>MA</given-names></name><name><surname>Rutter</surname><given-names>GA</given-names></name></person-group><article-title>Isolation and culture of mouse pancreatic islets for ex vivo imaging studies with trappable or recombinant fluorescent probes</article-title><source>Methods MolBiol</source><year>2010</year><volume>633</volume><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">20204627</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montana</surname><given-names>E</given-names></name><name><surname>Bonner-Weir</surname><given-names>S</given-names></name><name><surname>Weir</surname><given-names>GC</given-names></name></person-group><article-title>Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><fpage>780</fpage><lpage>787</lpage><pub-id pub-id-type="pmcid">PMC288028</pub-id><pub-id pub-id-type="pmid">8450059</pub-id><pub-id pub-id-type="doi">10.1172/JCI116297</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chabosseau</surname><given-names>P</given-names></name><name><surname>Yong</surname><given-names>F</given-names></name><name><surname>Delgadillo-Silva</surname><given-names>LF</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Melhem</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Gandhi</surname><given-names>N</given-names></name><name><surname>Wastin</surname><given-names>J</given-names></name><name><surname>Noriega</surname><given-names>LL</given-names></name><name><surname>Leclerc</surname><given-names>I</given-names></name><name><surname>Ali</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Molecular phenotyping of single pancreatic islet leader beta cells by “Flash-Seq”</article-title><source>Life Sci</source><year>2023</year><volume>316</volume><elocation-id>121436</elocation-id><pub-id pub-id-type="pmid">36706832</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delgadillo-Silva</surname><given-names>LF</given-names></name><name><surname>Tasöz</surname><given-names>E</given-names></name><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Chawla</surname><given-names>P</given-names></name><name><surname>Georgiadou</surname><given-names>E</given-names></name><name><surname>Gompf</surname><given-names>A</given-names></name><name><surname>Rutter</surname><given-names>GA</given-names></name><name><surname>Ninov</surname><given-names>N</given-names></name></person-group><article-title>Optogenetic ß cell interrogation in vivo reveals a functional hierarchy directing the Ca(2+) response to glucose supported by vitamin B6</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><elocation-id>ead04513</elocation-id><pub-id pub-id-type="pmcid">PMC11204215</pub-id><pub-id pub-id-type="pmid">38924394</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.ado4513</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Sheng</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study</article-title><source>Drug Des Devel Ther</source><year>2016</year><volume>10</volume><fpage>1619</fpage><lpage>1626</lpage><pub-id pub-id-type="pmcid">PMC4869670</pub-id><pub-id pub-id-type="pmid">27274195</pub-id><pub-id pub-id-type="doi">10.2147/DDDT.S105021</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Xi</surname><given-names>S</given-names></name></person-group><article-title>Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus</article-title><source>J Diabetes Res</source><year>2017</year><volume>2017</volume><elocation-id>5812607</elocation-id><pub-id pub-id-type="pmcid">PMC5278194</pub-id><pub-id pub-id-type="pmid">28191470</pub-id><pub-id pub-id-type="doi">10.1155/2017/5812607</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgiadou</surname><given-names>E</given-names></name><name><surname>Muralidharan</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Chabosseau</surname><given-names>P</given-names></name><name><surname>Akalestou</surname><given-names>E</given-names></name><name><surname>Tomas</surname><given-names>A</given-names></name><name><surname>Wern</surname><given-names>FYS</given-names></name><name><surname>Stylianides</surname><given-names>T</given-names></name><name><surname>Wretlind</surname><given-names>A</given-names></name><name><surname>Legido-Quigley</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><etal/></person-group><article-title>Mitofusins Mfnl and Mfn2 Are Required to Preserve Glucose-but Not Incretin-Stimulated ß-Cell Connectivity and Insulin Secretion</article-title><source>Diabetes</source><year>2022</year><volume>71</volume><fpage>1472</fpage><lpage>1489</lpage><pub-id pub-id-type="pmcid">PMC9233298</pub-id><pub-id pub-id-type="pmid">35472764</pub-id><pub-id pub-id-type="doi">10.2337/db21-0800</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>NR</given-names></name><name><surname>Mitchell</surname><given-names>RK</given-names></name><name><surname>Haythorne</surname><given-names>E</given-names></name><name><surname>Pessoa</surname><given-names>MP</given-names></name><name><surname>Semplici</surname><given-names>F</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name><name><surname>Piemonti</surname><given-names>L</given-names></name><name><surname>Marchetti</surname><given-names>P</given-names></name><name><surname>Bugliani</surname><given-names>M</given-names></name><name><surname>Bosco</surname><given-names>D</given-names></name><name><surname>Berishvilli</surname><given-names>E</given-names></name><etal/></person-group><article-title>Beta cell hubs dictate pancreatic islet responses to glucose</article-title><source>Cell Metabolism</source><year>2016</year><volume>24</volume><fpage>389</fpage><lpage>401</lpage><pub-id pub-id-type="pmcid">PMC5031557</pub-id><pub-id pub-id-type="pmid">27452146</pub-id><pub-id pub-id-type="doi">10.1016/j.cmet.2016.06.020</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Shelton</surname><given-names>KD</given-names></name></person-group><article-title>An alternate promoter in the glucokinase gene is active in the pancreatic beta cell</article-title><source>J Biol Chem</source><year>1989</year><volume>264</volume><fpage>15936</fpage><lpage>15942</lpage><pub-id pub-id-type="pmid">2550428</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorens</surname><given-names>B</given-names></name><name><surname>Tarussio</surname><given-names>D</given-names></name><name><surname>Maestro</surname><given-names>MA</given-names></name><name><surname>Rovira</surname><given-names>M</given-names></name><name><surname>Heikkila</surname><given-names>E</given-names></name><name><surname>Ferrer</surname><given-names>J</given-names></name></person-group><article-title>Insl knock-in mice for beta cell-specific gene recombination</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>558</fpage><lpage>656</lpage><pub-id pub-id-type="pmcid">PMC4320308</pub-id><pub-id pub-id-type="pmid">25500700</pub-id><pub-id pub-id-type="doi">10.1007/s00125-014-3468-5</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osbak</surname><given-names>KK</given-names></name><name><surname>Colclough</surname><given-names>K</given-names></name><name><surname>Saint-Martin</surname><given-names>C</given-names></name><name><surname>Beer</surname><given-names>NL</given-names></name><name><surname>Bellanné-Chantelot</surname><given-names>C</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Gloyn</surname><given-names>AL</given-names></name></person-group><article-title>Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinémie hypoglycemia</article-title><source>Hum Mutât</source><year>2009</year><volume>30</volume><fpage>1512</fpage><lpage>1526</lpage><pub-id pub-id-type="pmid">19790256</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valentinova</surname><given-names>L</given-names></name><name><surname>Beer</surname><given-names>NL</given-names></name><name><surname>Staník</surname><given-names>J</given-names></name><name><surname>Tribble</surname><given-names>ND</given-names></name><name><surname>van de Bunt</surname><given-names>M</given-names></name><name><surname>Hučková</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>A</given-names></name><name><surname>Klimeš</surname><given-names>I</given-names></name><name><surname>Gašperíková</surname><given-names>D</given-names></name><name><surname>Gloyn</surname><given-names>AL</given-names></name></person-group><article-title>Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><elocation-id>e34541</elocation-id><pub-id pub-id-type="pmcid">PMC3321013</pub-id><pub-id pub-id-type="pmid">22493702</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0034541</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Herrero</surname><given-names>CM</given-names></name><name><surname>Galán</surname><given-names>M</given-names></name><name><surname>Vincent</surname><given-names>O</given-names></name><name><surname>Flández</surname><given-names>B</given-names></name><name><surname>Gargallo</surname><given-names>M</given-names></name><name><surname>Delgado-Alvarez</surname><given-names>E</given-names></name><name><surname>Blázquez</surname><given-names>E</given-names></name><name><surname>Navas</surname><given-names>MA</given-names></name></person-group><article-title>Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">17186219</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>JR</given-names></name><name><surname>Shaw</surname><given-names>NJ</given-names></name><name><surname>Barrett</surname><given-names>TG</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Ellard</surname><given-names>S</given-names></name><name><surname>Gloyn</surname><given-names>AL</given-names></name></person-group><article-title>Permanent neonatal diabetes in an Asian infant</article-title><source>J Pediatr</source><year>2005</year><volume>146</volume><fpage>131</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">15644838</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raimondo</surname><given-names>A</given-names></name><name><surname>Chakera</surname><given-names>A</given-names></name><name><surname>Thomsen</surname><given-names>SK</given-names></name><name><surname>Colclough</surname><given-names>K</given-names></name><name><surname>Barrett</surname><given-names>A</given-names></name><name><surname>De Franco</surname><given-names>E</given-names></name><name><surname>Chatelas</surname><given-names>A</given-names></name><name><surname>Demirbilek</surname><given-names>H</given-names></name><name><surname>Akcay</surname><given-names>T</given-names></name><name><surname>Alawneh</surname><given-names>H</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Phenotypic severity of homozygous GCK mutations causing neonatal or childhood-onset diabetes is primarily mediated through effects on protein stability</article-title><source>Hum Mol Genet</source><year>2014</year><volume>23</volume><fpage>6432</fpage><lpage>6440</lpage><pub-id pub-id-type="pmcid">PMC4240195</pub-id><pub-id pub-id-type="pmid">25015100</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddu360</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekine</surname><given-names>N</given-names></name><name><surname>Cirulli</surname><given-names>V</given-names></name><name><surname>Regazzi</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>LJ</given-names></name><name><surname>Gine</surname><given-names>E</given-names></name><name><surname>Tamarit-Rodriguez</surname><given-names>J</given-names></name><name><surname>Girotti</surname><given-names>M</given-names></name><name><surname>Marie</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>MJ</given-names></name><name><surname>Wollheim</surname><given-names>CB</given-names></name><name><surname>Rutter</surname><given-names>GA</given-names></name></person-group><article-title>Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogease in pancreatic á-cell. Potential role in nutrient sensing</article-title><source>JBiolChem</source><year>1994</year><volume>269</volume><fpage>4895</fpage><lpage>4902</lpage><pub-id pub-id-type="pmid">8106462</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Bürck</surname><given-names>L</given-names></name><name><surname>Blutke</surname><given-names>A</given-names></name><name><surname>Kautz</surname><given-names>S</given-names></name><name><surname>Rathkolb</surname><given-names>B</given-names></name><name><surname>Klaften</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Kemter</surname><given-names>E</given-names></name><name><surname>Hrabé de Angelis</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>E</given-names></name><name><surname>Aigner</surname><given-names>B</given-names></name><name><surname>Wanke</surname><given-names>R</given-names></name><etal/></person-group><article-title>Phenotypic and pathomorphological characteristics of a novel mutant mouse model for maturity-onset diabetes of the young type 2 (MODY 2)</article-title><source>Am J Physiol Endocrinol Metab</source><year>2010</year><volume>298</volume><fpage>E512</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">19952346</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basco</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Salehi</surname><given-names>A</given-names></name><name><surname>Tarasov</surname><given-names>A</given-names></name><name><surname>Dolci</surname><given-names>W</given-names></name><name><surname>Herrera</surname><given-names>P</given-names></name><name><surname>Spiliotis</surname><given-names>I</given-names></name><name><surname>Berney</surname><given-names>X</given-names></name><name><surname>Tarussio</surname><given-names>D</given-names></name><name><surname>Rorsman</surname><given-names>P</given-names></name><name><surname>Thorens</surname><given-names>B</given-names></name></person-group><article-title>alpha-cell glucokinase suppresses glucose-regulated glucagon secretion</article-title><source>NatCommun</source><year>2018</year><volume>9</volume><fpage>546</fpage><elocation-id>03034</elocation-id><pub-id pub-id-type="pmcid">PMC5803227</pub-id><pub-id pub-id-type="pmid">29416045</pub-id><pub-id pub-id-type="doi">10.1038/s41467-018-03034-0</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimann</surname><given-names>F</given-names></name><name><surname>Gribble</surname><given-names>FM</given-names></name></person-group><article-title>Glucose-sensing in glucagon-like peptide-l-secreting cells</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>2757</fpage><lpage>2763</lpage><pub-id pub-id-type="pmid">12196469</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Shepherd</surname><given-names>RM</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name><name><surname>Gorman</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Dunne</surname><given-names>MJ</given-names></name></person-group><article-title>Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>1694</fpage><lpage>1702</lpage><pub-id pub-id-type="pmid">17360975</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Article Highlights</title></caption><p><list list-type="alpha-lower" id="L1"><list-item><p>Glucokinase deficiency can drive maturity-onset diabetes of the young (GCK- MODY; <italic>heterozygotes</italic>) and permanent neonatal diabetes (GCK-PNDM; <italic>homozygotes</italic>)</p></list-item><list-item><p>We describe a hypomorphic <italic>Gck</italic> allele where aberrant splicing in islets lowers GK activity to by ~85%. We use these mice to explore the effects of the glucokinase activator, dorzagliatin, and incretin on insulin secretion</p></list-item><list-item><p>Whereas heterozygous mutant mice are mildly hyperglycemic, homozygotes have frank diabetes but survive to adulthood. Dorzagliatin potentiates the effects of GLP-1 receptor activation sex-dependently in heterozygotes</p></list-item><list-item><p>Combined use of these drugs may be useful in some forms of <italic>GCK</italic> diabetes</p></list-item></list></p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Design and genomic map of the Gck<sup>KI</sup> mouse allele.</title><p><bold>A)</bold> The 3’ <italic>Glucokinase</italic> (<italic>Gck</italic>) coding sequence comprising exon-4 to exon-10 was directly fused in frame with endogenous exon-3. This was followed by an IRES, mCardinal cDNA and termination signal plus human growth hormone (hGH) polyA. The construct is expected to produce a single bicistronic mRNA expressing Glucokinase and mCardinal from the same mRNA transcript. <bold>B)</bold> Wildtype <italic>Gck</italic> mRNA structure. <bold>C)</bold> Observed sequence expressed from the knock-in allele. Sanger sequencing of the <italic>Gck</italic> PCR product from Gck<sup>KI/KI</sup> islet cDNA revealed alternative splicing in which exon 2 and exon 3 are skipped. Alpha-fold predicted 3D structure of <bold>D)</bold> wildtype mouse glucokinase and <bold>E)</bold> the mis-spliced isoform. The green matrix represents the confidence in the prediction in Angstroms, with darker shades indicating greater confidence. The beta-barrel that forms part of the glucose-binding pocket and ATP binding domain (pink, D) is absent from the modelled misspliced isoform (E).</p></caption><graphic xlink:href="EMS200057-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Apparent GK protein levels in male and female pancreatic islets.</title><p><bold>A)</bold> Western (immuno-) blot images from islets protein from wildtype, Gck<sup>KI/+</sup> (heterozygous) and Gck<sup>KI/KI</sup> (homozygous) males and females. Glucokinase was detected at ~48kDa and beta-actin at ~45kDa. <bold>B)</bold> Quantitative analysis of GK expression levels normalized to beta-actin across sex and genotype. Each dot represents a single animal. Unpaired one-way ANOVA with Tukey’s correction. *<italic>P ≤</italic> .05, **<italic>P ≤</italic> .01, ***<italic>P ≤</italic> .001.</p></caption><graphic xlink:href="EMS200057-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Metabolic characterization of Gck<sup>KI/+</sup> and Gck<sup>KI/KI</sup> mice.</title><p><bold>A)</bold> Representative images across male genotypes. <bold>B)</bold> Mouse weight at 8 weeks of age across sex and genotype, <italic>n</italic>=15 WT, 10 Het and 4 Homo. Females, <italic>n</italic>=13 WT, 13 Het and 5 Homo. <bold>C)</bold> HbA1c at 8-16w across sex and genotype. Homozygous animals exhibit a diabetic phenotype in both males and females (HbA1c% &gt; 10). Males, <italic>n</italic>=7 WT, 8 Het, and 8 Homo. Females, <italic>n</italic>=5 WT, 6 Hets and 8 Homo. Unpaired one-way ANOVA with Tukey’s correction. <bold>D)</bold> Intraperitoneal glucose tolerance tests (IPGTT) with 2 g/kg glucose performed at 8-16w of age for males (<italic>n</italic>=12 WT and 9 Hets) and females (<italic>n</italic>=12 WT and 13 Hets). Unpaired one-way ANOVA with Šidák’s correction. <bold>E)</bold> Glucose excursion (area under the curve, AUC) quantifications from the male and female IPGTTs presented in (D). Unpaired one-way ANOVA with Tukey’s correction. <bold>F)</bold> Intraperitoneal insulin tolerance test (IPTT) with 0.75 insulin units/Kg performed at 8-16w. Males, <italic>n</italic>=10 WT, 6 Hets. Females, <italic>n</italic>=7 WT, 7 Hets. Unpaired two-way ANOVA with Šidák’s correction. <bold>G)</bold> Glucose AUC quantifications of IPGTTs presented in (F). Unpaired oneway ANOVA with Tukey’s correction. The homozygous fasting values are represented by the red triangle (<italic>n</italic>=3 mice) in (D) and (F). Due to the high fasting glucose, IPGTT and IPTT were not performed in homozygotes, and the fasting glucose levels are presented as a reference only. <bold>H)</bold> Insulin secretion from isolated islets across genotypes and sexes. * (I) Ketone body levels in fasted animals. <italic>N</italic>=3-5 per group. <italic>P</italic> ≤ .05, **<italic>P</italic> ≤ .01, ***<italic>P ≤</italic> .001, ****<italic>P ≤</italic> .0001.</p></caption><graphic xlink:href="EMS200057-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Dorzagliatin restores glucose-induced Ca<sup>2+</sup> dynamics and β-cell connectivity in Gck<sup>KI/+</sup> mouse islets.</title><p><bold>A)</bold> Experimental design for <italic>in vitro</italic> calcium imaging in islets from 8-16w Ins1Cre:GCaMP6ff<sup>l/fl</sup>:Gck<sup>+/+</sup> (“WT”), Gck<sup>KI/+</sup> (“Het”) and Gck<sup>KI/+</sup> (“Homo”) triple transgenic mice. Where indicated, isolated islets were treated for 1h with 10μM dorzagliatin prior to imaging. <bold>B)</bold> Snapshots from confocal time-lapses recordings of the individual islets at 6 Hz in 11mM glucose with or without 10μmol/L dorzagliatin across <italic>Gck</italic> genotypes. <bold>C)</bold> Normalized GCaMP6f fluorescence traces from islets shown in (B). <bold>C)</bold> Raster plots show the apparent Ca<sup>2+</sup> signal for individual cells from islets shown in (B). <bold>D)</bold> Visualization of the islet functional network for each genotype, with or without dorzagliatin, from islets displayed in (B). <bold>E)</bold> Calcium AUC quantification across genotypes in control and dorzagliatin treated islets. <bold>F)</bold> Connectivity quantifications across genotypes in control and dorzagliatin treatment groups. Unpaired one-way ANOVA with Tukey’s correction. *<italic>P ≤</italic> .05, **<italic>P ≤</italic> .01, ***<italic>P ≤</italic> .001, ****<italic>P ≤</italic> .0001. For 11 mmol/L glucose-only treatment, <italic>n</italic>=5 WT mice (9 islets), n=8 heterozygotes (14 islets) and n=4 homozygotes (7 islets). For dorzagliatin treatment, <italic>n</italic>=4 WT (6 islets), <italic>n</italic>=5 heterozygotes (13 islets) and <italic>n</italic>=4 homozygotes (11 islets). Each dot represents an individual islet. The numbers 1, 2, and 3 in the snapshots displayed in (B) indicate the time points corresponding to the fluorescence traces showed in (C). Scale bar, 25 μm.</p></caption><graphic xlink:href="EMS200057-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Impact of dorzagliatin and exendin-4 on glucose tolerance across genotypes and sexes.</title><p><bold>A-B)</bold> Intraperitoneal glucose tolerance test (IPGTT) with 2 g/kg glucose performed in animals of 8-16w of age for males and females after injection of glucose only or glucose in combination with dorzagliatin (1mg/kg), exendin-4 (1nmol/kg) or dorzagliatin (1mg/kg) + exendin-4 (1nmol/kg) in WT (Gck<sup>+/+</sup>) or heterozygous (Gck<sup>KI/+</sup>) animals. The first panel in grey corresponds to the same data shown in <xref ref-type="fig" rid="F3">Fig. 3D</xref>. Unpaired two-way ANOVA with Šidák’s correction. <bold>C-D)</bold> Glucose AUC quantifications of each IPGTT treatment from male and female mice presented in (A) and (B). Males, <italic>n</italic>=4 WT, 7 Hets for each treatment; Females, <italic>n</italic>=5 WT, 10 Hets for each treatment. Unpaired one-way ANOVA with Tukey’s correction. <bold>E)</bold> Glucose AUC quantifications of each IPGTT treatment from pooled male and female mice presented in (A) and (B), and homozygous (Gck<sup>KI/KI</sup>) mice treated with PBS alone, or PBS and dorzagliatin (1mg/kg), exendin-4 (1nmol/kg) or dorzagliatin (1mg/kg) + exendin-4 (1nmol/kg). Males: <italic>n</italic>=4 WT, <italic>n</italic>=4 Hets, <italic>n</italic>=2 Homo for each treatment, <italic>n</italic>=1-Homo (PBS); Females <italic>n</italic>=7 WT, <italic>n</italic>=7 Hets, <italic>n</italic>=5 Homo for each treatment, <italic>n</italic>=4 Homo (PBS). Unpaired one-way ANOVA with Tukey’s correction. *P ≤ .05, **P ≤ .01, ***P ≤ .001, ****P ≤ .0001 *<italic>P ≤</italic> .05, **<italic>P ≤</italic> .01, ***<italic>P</italic> ≤ .001, ****<italic>P ≤</italic> .0001.</p></caption><graphic xlink:href="EMS200057-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Impact of dorzagliatin and incretin on glucose-stimulated insulin secretion <italic>in vitro</italic>.</title><p><bold>A-B)</bold> Insulin secretion <italic>in vitro</italic> for male (A) and female (B) at low (3mmol/L) and high (17mmol/L) glucose concentrations. <bold>C)</bold> Stimulation index, calculated as the ratio of insulin secreted at 17 mmol/L glucose to that at 3 mmol/L glucose, from pooled islets of both sexes across genotypes. One-way ANOVA of Brown-Forsythe. Mean ± SD. *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001, ****P&lt;0.0001.</p></caption><graphic xlink:href="EMS200057-f006"/></fig></floats-group></article>